Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EUDA Health Holdings Limited (EUDAW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. EUDA files current reports on Form 6-K under the Securities Exchange Act of 1934, which furnish information about material events, financing transactions, and other matters related to its Singapore-based health technology business and Southeast Asian digital healthcare ecosystem.
In these filings, EUDA has described entering into an At The Market Offering Agreement that allows it to issue and sell ordinary shares through a sales agent, as well as a convertible promissory note purchase agreement under which notes are convertible into newly issued ordinary shares at a discount to the trading price, subject to specified conditions. The company’s 6-K reports also reference a shelf registration statement on Form F-3, with certain agreements and legal opinions incorporated by reference into that registration statement and related prospectus supplements.
Filings on this page may also include reports of press releases furnished as exhibits, such as announcements about Nasdaq listing delinquency letters tied to delayed Form 10-K and Form 10-Q filings. While those periodic reports are filed separately, the 6-K disclosures explain the listing rule framework and the company’s responses.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms in documents like Form 6-K, describe the structure of at-the-market offerings and convertible notes, and clarify how these instruments relate to EUDA’s ordinary shares and warrants. Users can review new filings as they appear on EDGAR, see how specific agreements affect EUDAW-related securities, and use AI-generated insights to navigate complex legal and financing language more efficiently.
EUDA Health Holdings Limited filed a Form 6-K highlighting that Shenzhen Inno Immune Co., Ltd. has received official approval under the 2025 Shenzhen Key Industry R&D Program for a TCR-T cell therapy project targeting solid tumors.
The project is scheduled to run from January 1, 2026 to December 31, 2028 and may receive up to approximately US$434,688 in government funding from the Shenzhen Science and Technology Innovation Bureau. Under a non-exclusive distribution arrangement, EUDA holds rights to market and sell selected Shenzhen Inno immunotherapies to customers in Malaysia via its subsidiary CK Health Plus Sdn Bhd, with treatments conducted in China.
Management explains that this aligns with EUDA’s strategy to expand access to advanced, science-driven therapies and supports its broader focus on preventive and longevity-focused healthcare across Asia.
EUDA Health Holdings Limited filed a Form 6-K highlighting that Shenzhen Inno Immune Co., Ltd. has received official approval under the 2025 Shenzhen Key Industry R&D Program for a TCR-T cell therapy project targeting solid tumors.
The project is scheduled to run from January 1, 2026 to December 31, 2028 and may receive up to approximately US$434,688 in government funding from the Shenzhen Science and Technology Innovation Bureau. Under a non-exclusive distribution arrangement, EUDA holds rights to market and sell selected Shenzhen Inno immunotherapies to customers in Malaysia via its subsidiary CK Health Plus Sdn Bhd, with treatments conducted in China.
Management explains that this aligns with EUDA’s strategy to expand access to advanced, science-driven therapies and supports its broader focus on preventive and longevity-focused healthcare across Asia.
EUDA Health Holdings Limited files its annual Form 20-F for the year ended December 31, 2025, highlighting ongoing financial strain and strategic shifts. The company reports a net loss of approximately $2.8 million for 2025, following a $15.4 million loss in 2024, and discloses a working capital deficit of about $4.8 million with only $0.3 million in cash.
EUDA’s auditor raises substantial doubt about its ability to continue as a going concern, and management acknowledges material weaknesses in internal control over financial reporting. Nasdaq has notified the company that it failed to maintain the required $35 million Minimum Market Value of Listed Securities; EUDA must regain compliance by October 20, 2026 to avoid potential delisting.
The report describes a strategic move from medical services to wellness, including the $15.0 million all-share acquisition of CK Health, which generated roughly $2.0 million of 2025 revenue, and reliance on Southeast Asian wellness and planned stem cell offerings. EUDA also details multiple equity and convertible financings, a 1-for-20 reverse stock split, and an agreement to purchase 16 million QB utility tokens using cash and shares, underscoring its need for ongoing external funding.
EUDA Health Holdings Limited files its annual Form 20-F for the year ended December 31, 2025, highlighting ongoing financial strain and strategic shifts. The company reports a net loss of approximately $2.8 million for 2025, following a $15.4 million loss in 2024, and discloses a working capital deficit of about $4.8 million with only $0.3 million in cash.
EUDA’s auditor raises substantial doubt about its ability to continue as a going concern, and management acknowledges material weaknesses in internal control over financial reporting. Nasdaq has notified the company that it failed to maintain the required $35 million Minimum Market Value of Listed Securities; EUDA must regain compliance by October 20, 2026 to avoid potential delisting.
The report describes a strategic move from medical services to wellness, including the $15.0 million all-share acquisition of CK Health, which generated roughly $2.0 million of 2025 revenue, and reliance on Southeast Asian wellness and planned stem cell offerings. EUDA also details multiple equity and convertible financings, a 1-for-20 reverse stock split, and an agreement to purchase 16 million QB utility tokens using cash and shares, underscoring its need for ongoing external funding.
EUDA Health Holdings Limited reported that Nasdaq notified the company on April 23, 2026 that it failed to maintain the required Minimum Market Value of Listed Securities of $35 million for 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). The notice does not immediately affect trading, and EUDA has 180 calendar days, until October 20, 2026, to regain compliance by having its market value close at $35,000,000 or more for at least ten consecutive business days. If EUDA does not regain compliance within this period, its securities will be subject to potential delisting, although the company would have the right to appeal.
EUDA Health Holdings Limited reported that Nasdaq notified the company on April 23, 2026 that it failed to maintain the required Minimum Market Value of Listed Securities of $35 million for 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). The notice does not immediately affect trading, and EUDA has 180 calendar days, until October 20, 2026, to regain compliance by having its market value close at $35,000,000 or more for at least ten consecutive business days. If EUDA does not regain compliance within this period, its securities will be subject to potential delisting, although the company would have the right to appeal.
EUDA Health Holdings Limited approved and is implementing a 1-for-20 reverse stock split of its ordinary shares, effective at market open on March 23, 2026 on the Nasdaq Capital Market. The company states that shareholder ownership percentages and voting power will remain substantially the same aside from minor rounding effects.
Shares outstanding will be reduced from approximately 50,307,491 to approximately 2,515,375, with fractional shares rounded up and no cash paid in lieu. EUDA’s outstanding warrants will be adjusted proportionately, cutting underlying shares from about 4,458,625 to about 222,932 while increasing the exercise price from $11.50 to $230.00 per share equivalent.
EUDA Health Holdings Limited approved and is implementing a 1-for-20 reverse stock split of its ordinary shares, effective at market open on March 23, 2026 on the Nasdaq Capital Market. The company states that shareholder ownership percentages and voting power will remain substantially the same aside from minor rounding effects.
Shares outstanding will be reduced from approximately 50,307,491 to approximately 2,515,375, with fractional shares rounded up and no cash paid in lieu. EUDA’s outstanding warrants will be adjusted proportionately, cutting underlying shares from about 4,458,625 to about 222,932 while increasing the exercise price from $11.50 to $230.00 per share equivalent.
EUDA Health Holdings Ltd Chief Financial Officer Tay Whye Shin has filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. The filing establishes this officer’s reporting status under SEC rules but does not report any stock transactions.
EUDA Health Holdings Ltd Chief Financial Officer Tay Whye Shin has filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. The filing establishes this officer’s reporting status under SEC rules but does not report any stock transactions.
EUDA Health Holdings Ltd director Liew Kwong Yeow filed an initial ownership report showing direct holdings of 3,000 Ordinary Shares. This Form 3 does not report any recent buy or sell transactions; it simply establishes his current equity stake in the company.
EUDA Health Holdings Ltd director Liew Kwong Yeow filed an initial ownership report showing direct holdings of 3,000 Ordinary Shares. This Form 3 does not report any recent buy or sell transactions; it simply establishes his current equity stake in the company.
EUDA Health Holdings Ltd director Lew Chern Yong has filed a Form 3, which records his status as an insider of the company. The provided data does not list any equity transactions or derivative positions, and the transaction summary shows no buys, sells, or other reportable trades.
EUDA Health Holdings Ltd director Lew Chern Yong has filed a Form 3, which records his status as an insider of the company. The provided data does not list any equity transactions or derivative positions, and the transaction summary shows no buys, sells, or other reportable trades.
EUDA Health Holdings Ltd director Huang Bo filed an initial statement of beneficial ownership as a new insider. This Form 3 filing does not report any share purchases, sales, or other transactions, and instead serves to formally register Huang Bo’s status as a reporting person for EUDA Health.
EUDA Health Holdings Ltd director Huang Bo filed an initial statement of beneficial ownership as a new insider. This Form 3 filing does not report any share purchases, sales, or other transactions, and instead serves to formally register Huang Bo’s status as a reporting person for EUDA Health.
EUDA Health Holdings Limited completed a registered offering of 12,500,000 ordinary shares for an aggregate purchase price of $3,750,000, using its Form F-3 shelf registration and a March 2026 prospectus supplement. The company plans to use the net proceeds for general corporate purposes, including possible acquisitions, business expansion and working capital.
Separately, EUDA repurchased in full a previously issued warrant that was exercisable for 2,000,000 newly issued ordinary shares, paying $125,000 on February 27, 2026, and the warrant was cancelled. The report also incorporates this information by reference into the company’s existing Form F-3 registration statement.
EUDA Health Holdings Limited completed a registered offering of 12,500,000 ordinary shares for an aggregate purchase price of $3,750,000, using its Form F-3 shelf registration and a March 2026 prospectus supplement. The company plans to use the net proceeds for general corporate purposes, including possible acquisitions, business expansion and working capital.
Separately, EUDA repurchased in full a previously issued warrant that was exercisable for 2,000,000 newly issued ordinary shares, paying $125,000 on February 27, 2026, and the warrant was cancelled. The report also incorporates this information by reference into the company’s existing Form F-3 registration statement.
EUDA Health is registering 12,500,000 ordinary shares in a registered direct offering. The offering is being made pursuant to Securities Purchase Agreements dated February 24 and 25, 2026 and is being issued directly to accredited investors without a placement agent.
The company estimates net proceeds of approximately $3,692,000. As of the date of this Prospectus Supplement there were 37,807,491 Ordinary Shares outstanding; the company states there will be 50,307,491 Ordinary Shares issued and outstanding after this offering. The Ordinary Shares trade on Nasdaq under the symbol EUDA; the cited closing price on February 27, 2026 was $0.9747.
EUDA Health is registering 12,500,000 ordinary shares in a registered direct offering. The offering is being made pursuant to Securities Purchase Agreements dated February 24 and 25, 2026 and is being issued directly to accredited investors without a placement agent.
The company estimates net proceeds of approximately $3,692,000. As of the date of this Prospectus Supplement there were 37,807,491 Ordinary Shares outstanding; the company states there will be 50,307,491 Ordinary Shares issued and outstanding after this offering. The Ordinary Shares trade on Nasdaq under the symbol EUDA; the cited closing price on February 27, 2026 was $0.9747.